Baseline cardiac output and its alterations during ibuprofen treatment for patent ductus arteriosus in preterm infants
BMC Pediatrics volume 19, Article number: 179 (2019)
Infants with hemodynamically significant patent ductus arteriosus (PDA) may physiologically compensate with a supranormal cardiac output (CO). As such, a supranormal CO may be a surrogate marker for a significant PDA or indicate a failed response to PDA closure by ibuprofen. Electrical cardiometry (EC) is an impedance-based monitor that can continuously and non-invasively assess CO (COEC). We aimed to trend COEC through ibuprofen treatment for PDA in preterm infants.
We reviewed our database of preterm infants receiving ibuprofen for PDA closure. Response to ibuprofen was defined as no ductal flow in echocardiography ≤24 h after treatment. Responders were compared with gestational age (GA) and postnatal age matched non-responders and their trends of COEC were compared. Both groups’ baseline COEC were further compared to the reference infants without PDA.
Eighteen infants (9 responders and 9 non-responders) with median (interquatile range) GA 27.5 (26.6–28.6) weeks, birthweight 1038 (854–1218) g and age 3.5 (3.0–4.0) days were studied. There were positive correlations between COEC and ductal diameter and left atrium/ aortic root ratio (r = 0.521 and 0.374, p < 0.001, respectively). Both responders and non-responders had significantly higher baseline COEC than the reference. Although there was no significant within-subject alteration of COEC during ibuprofen treatment, there was a between-subject difference indicating non-responders had generally higher COEC.
The changes of COEC during pharmacological closure of PDA is less drastic compared to surgical closure. Infants with PDA had higher baseline COEC compared to those without PDA, and non-responders had higher COEC especially at baseline compared to responders.
Patent ductus arteriosus (PDA) is common among preterm infants and failure of ductal closure is associated with complications and poor outcomes . Non-selective cyclooxygenase (COX) inhibitor, such as ibuprofen, is the pharmacological choice of treatment for PDA based on its action of prostaglandin inhibition that promotes ductal constriction. Both the intravenous and oral routes of ibuprofen administration appear comparably effective for ductal closure . However, successful PDA closure by pharmacological treatment is not always definite or predictable . The rate of ductal closure after COX inhibitors varies from 60 to 85% in preterm infants and is even less effective in extremely premature infants [4,5,6].
Echocardiography is often used to evaluate hemodynamic significance of PDA . In general, pharmacological closure of PDA is less successful in infants with ductal diameter > 2 mm . Lower ductal maximum velocity, which is usually associated with a larger PDA or higher pulmonary pressure, is another predictor of treatment failure [4, 8]. Furthermore, an increase in left ventricular cardiac output (CO) has been positively correlated with significant ductal shunting [7, 9, 10] and PDA severity . The underlying reason is that a PDA with significant left-to-right flow may lead to a compensatory increase in CO in order to maintain systemic blood flow [12, 13]. Indeed, following closure of ductus after COX inhibitor therapy  or surgical ligation [10, 14], CO normalizes accordingly. We therefore hypothesized that a supranormal CO in the first week of life in extreme premature infants may indicate a hemodynamically significant PDA and that we could observe CO changes during pharmacological treatment. However, the ability to perform neonatal functional echocardiography requires practice, training and mentorship . Furthermore, the use of echocardiography to gather meaningful hemodynamic data often necessitates serial assessments that can be tedious and labor-intensive.
Electrical cardiometry (EC) is a non-invasive, impedance-based monitor that provides absolute CO estimates in clinical practice . Unlike echocardiography, EC is simple to apply, continuous in measurements and not operator-dependent. Comparisons between CO measured by EC (COEC) and echocardiography have been studied in term  and preterm [18,19,20] infants with and without PDA. Although CO values measured by EC and echocardiography may not be interchangeable, it has been suggested that EC can be useful in trending CO changes in the clinical setting . Hemodynamic reference by EC for neonates without PDA and without invasive ventilation support has been established, and COEC is positively correlated with gestational age (GA) and weight . In addition, EC was used to monitor the effects of ductal ligation on COEC, which revealed an initial decline in COEC followed by recovery . Utilizing the ability of EC to continuously measure COEC, we aimed to identify significant changes in COEC during attempted pharmacological closure and compared COEC characteristics in responders versus non-responders.
This study was conducted in the neonatal intensive care unit of Chang Gung Memorial Hospital Linkou Branch and was approved by the Institutional Review Board. As part of a hemodynamic monitoring project in the unit, echocardiographic findings and relevant hemodynamic information were collected prospectively into a database. We reviewed this database for very low birth weight (VLBW, < 1500 g) preterm infants admitted between June 2015 to June 2016 who received ibuprofen treatment for PDA closure. We enrolled infants who had both echocardiography and EC data during the first treatment course. Infants with chromosomal anomaly or structural heart defect other than small patent foramen ovale or atrial septal defect were excluded. Demographic data, serial echocardiographic findings and respiratory support at time of ibuprofen administration were collected.
Ibuprofen for PDA closure
The decision to initiate ibuprofen for PDA closure was made based on individual’s clinical condition (e.g. increased respiratory support or hypotension) and echocardiographic finding (e.g. large ductus > 2 mm or low peak systolic ductal flow). Per unit policy, infants with right-to-left or bidirectional shunting PDA, intraventricular hemorrhage grade ≥ 3 or poor renal function (serum creatinine > 1.8 mg/dl or oligouria < 1 ml/kg/hr) were not candidates for ibuprofen treatment. The decision to treat with oral (ibuprofen oral suspension, [Center Laboratories Inc., Taipei, Taiwan]) or intravenous ibuprofen (Ibusine: Ibuprofen Lysine, [China Chemical & Pharmaceutical Co., Taipei, Taiwan]) was also made by the attending neonatologist. One course of treatment for both oral and intravenous ibuprofen consisted of three consecutive doses of 10, 5, 5 mg/kg/dose given 24 h apart. Responder to ibuprofen treatment was defined as absence of ductal flow in echocardiography within 24 h after completion of treatment.
Transthoracic echocardiography was performed using Sonos 7500 (Philips, Andover, Massachusetts, USA) with a 12 MHz transducers. Serial echocardiography was performed in relation to ibuprofen administration: within an hour prior to dose #1 ibuprofen (baseline), 18–24 h after dose #1 and #2 (during treatment), and 24 h after dose #3 of ibuprofen (treatment completion). This timeframe was chosen to allow maximum effect of each dose. Echocardiographic parameters of the PDA were assessed, which includes ductal size and shunt direction by color Doppler mapping, maximum flow velocity by pulsed-wave Doppler, and left atrium to aortic root ratio (LA/Ao) and left ventricular fractional shortening (FS) by M-mode.
Electrical Cardiometry (EC)
EC (Aesculon, Osypka Medical, Berlin, Germany) was applied by attaching four standard surface electrocardiogram electrodes over the forehead, left lower neck, left mid-axillary line at the level of xiphoid process and lateral aspect of left thigh. EC was placed at least 1 h prior to dose #1 ibuprofen and kept in situ until 24 h after completing treatment. Hemodynamic parameters by EC, including COEC, heart rate (HREC) and stroke volume (SVEC) were captured every 10 min during the study period and subsequently exported into a database using software Waveform Explorer by Osypka Medical. The original data that 1 h before treatment and 18–24 h after each ibuprofen dose were further averaged and analyzed (e.g. the baseline and 18–24 h following dose #1, #2 and #3, respectively). Value of COEC and SVEC were weight-adjusted as ml/kg/min and ml/kg.
In order to minimize confounders related to GA, weight and post-natal age, we matched each responder to a non-responder with comparable GA ± 1 week, weight ± 10% g and post-natal age ± 7 days from the hemodynamic database. Furthermore, for comparison of COEC between infants with and without PDA, we also matched above responders and non-responders respectively to our previously published reference  using the same criteria.
Statistical analysis was performed using IBM SPSS Statistics version 20 (Armonk, NY, USA). Continuous variables in background demographics were tested using Mann-Whitney U test, while hemodynamic parameters by EC were tested with independent t-test between responders and non-responders or paired t-test was between two timing points. Repeated measures analysis of variance (RM-ANOVA) was applied to compare trends of hemodynamic parameters through the course. Categorical data were analyzed with Chi-square test or Fisher’s exact test. Analysis of the relationship between COEC and ductal diameter or LA/Ao was by Pearson correlation coefficient. One-way ANOVA with Bonferroni correction was used to compare COEC among responders, non-responders and the reference. Statistical significance was defined as two-sided p < 0.05.
During the study period, 303 VLBW preterm infants were admitted to our unit, of which 46 received ibuprofen treatment. There was complete data collection for both echocardiography and EC in 36 infants, and 11 of them were responders. After screening and matching, 9 out of 11 responders could be matched to 9 non-responders, and a total of 18 preterm infants were included. Their median (interquartile range) GA, weight and post-natal age at initiation of ibuprofen were 27.5 (26.6–28.6) weeks, 1038 (854–1218) g and 3.5 (3.0–4.0) days old, respectively. There was no significant difference in demographics, echocardiographic measurements, post-natal age, route of ibuprofen or respiratory support between responders and non-responders (Table 1). None received vasopressor or inotrope during the treatment course. Among 9 responders, 5 infants were found to have absence of ductal flow after dose #1 ibuprofen, 2 infants after dose #2, and 2 infants after dose #3 (Fig. 1 a–d). Furthermore, there was positive correlations between COEC and ductal diameter (r = 0.521, p < 0.001) and LA/Ao (r = 0.374, p < 0.001).
Non-responders had higher COEC compared to responders throughout the treatment course (RM-ANOVA between-subject p = 0.005). This discrepancy was most significant prior to ibuprofen treatment (282 ± 21 vs. 250 ± 31 ml/kg/min, p = 0.022), at 24 h post dose #2 (257 ± 33 vs. 226 ± 23 ml/kg/min, p = 0.034), and 24 h post dose #3 (270 ± 39 vs. 232 ± 14 ml/kg/min, p = 0.022) (Fig. 2a). No significant differences in HREC or SVEC were found between the two groups (Fig. 2b and c).
When analyzing within-subject changes throughout the treatment course, there were no significant changes of COEC, HREC or SVEC in either responders or non-responders (RM-ANOVA). The average alteration of COEC was − 7% ± 12% for responders and − 6% ± 16% for non-responders. On the other hand, when comparing baseline COEC to the earliest time point when no ductal flow was visualized by echocardiography, there was a significant but small-scale reduction in COEC by 25 ml/kg/min or 10% (250 ± 31 vs. 225 ± 17 ml/kg/min, paired t-test p = 0.031) (Table 2). However, we found 4/9 (44%) of non-responders had > 10% reduction of COEC at some timing points as well.
Another 18 infants without PDA were matched for baseline COEC comparison. Their median GA and weight were 28.6 (28.0–30.2) weeks and 1175 (1005–1312) g, respectively, and were all 3–4 days old. No demographic difference existed among these three groups (responders, non-responders and the reference). There was a significant stepwise increment in baseline COEC from infants with no PDA (207 ± 28 ml/kg/min), to infants with PDA, responders (250 ± 31 ml/kg/min), to infants with PDA, non-responders (282 ± 21 ml/kg/min, p < 0.001) (Fig. 3).
In this study, we showed the potential of EC to continuously monitor changes in COEC among preterm infants. By carefully matching target infants, we demonstrated that infants with PDA had higher baseline COEC and there was no significant COEC alteration during ibuprofen treatment for ductal closure.
Our finding indicated that preterm infants with PDA have significantly higher baseline COEC compared to age-matched reference, and that baseline COEC is positively correlated to PDA diameter and LA/Ao. The positive correlation suggests that infants with greater COEC have a higher likelihood of more significant ductal shunting. It was interesting to find that only the baseline COEC, but not ductal diameter, maximum ductal flow or LA/Ao, was significantly different between responders and non-responders in our study. It can be reasoned that with high left-to-right ductal shunting, CO represents the sum of systemic flow plus ductal shunting, and hence increases in CO is a compensation and proportional to ductal shunting [7, 13]. Furthermore, only COEC but not HREC or SVEC was significantly different between responders and non-responders. This may indicate that CO represents the sum of left ventricular work, i.e., HR and SV, to compensate for the ductal steal effect. It also suggests that CO may be a more comprehensive surrogate in determining the degree of ductal shunting. The difference in baseline COEC between responders and non-responders is compatible with previous studies that infants with larger ductal shunting may response poorly to COX inhibitor [4, 8].
We observed no significant COEC alteration through ibuprofen treatment for PDA closure. Although there was a mean decrease of COEC by 10% on initial ductal closure, this reduction of COEC cannot be an indicator for ductal closure because non-responders may also had > 10% reduction of COEC through the course. Moreover, the small-scale decline is unlike our previous study that a 26% decrease in COEC at time of ductal ligation . We speculate that the effect of ibuprofen in inducing ductal closure was progressive or intermittent while allowing time for the myocardium to adapt to the hemodynamic changes. This is further supported by the fact that no infant in our study required inotropic support, which is needed in infants with post-ligation hemodynamic instability.
There is a similar study utilizing EC to monitor CO during attempted pharmacological closure of PDA by intravenous ibuprofen in preterm infants , of which, a fall in median COEC from 290 to 240 ml/kg/min (17%) 72 h after the initiation of treatment was found. However, the study is limited by its small case number (6 responders) and a wide overlap of COEC between baseline and 72 h after the first dose ibuprofen. In addition, 2 out of 6 infants in this study received dopamine infusion before ibuprofen treatment and dopamine was tapered off at the end of ibuprofen treatment, which can confound the baseline and post-treatment COEC measurements . The dopamine infusion may have contributed to the larger discrepancy between baseline and post-treatment COEC in this study.
Some limitations should be addressed. Firstly, the sample size of current study was small. The number of responders limited the power to demonstrate exact COEC changes and to detect a confident cut-off COEC to assess treatment response. Secondly, using echocardiography to detect the exact timing of ductal closure during ibuprofen treatment is clinically complex. We are only able to use the earliest available echocardiography data that indicates no ductal flow to assess COEC alteration. This also limited the ability to estimate short-term alteration following ductal closure. We also lacked other echocardiographic markers for PDA severity such as superior vena cava flow for systemic blood flow  or left pulmonary artery end-diastolic flow for pulmonary overcirculation . Thirdly, some demographic information was not included into analysis. Closure of PDA is a multifactorial interaction, complete respiratory evaluation inclusive of arterial blood gas analysis, inhaled oxygen fraction and mean airway pressure, and even genetic disposition or pharmacokinetic difference should be considered. Lastly, we merely analyzed infants who received the first treatment course. Since it is known that the ibuprofen response is accumulative, it is warranted to enroll those receiving repeated courses in a future study.
The decrease in COEC during pharmacological closure of PDA is less drastic. Baseline CO measured by EC is higher in infants with PDA compared to those without PDA, especially non-responders had higher COEC at baseline compared to responders. Monitoring COEC is clinically applicable in bedside hemodynamic trending; however, a detailed assessment of hemodynamic compensation to a significant ductal shunt and to estimate pharmacological closure of the duct requires further studies.
Availability of data and materials
The dataset supporting the conclusions of this article is available by inquiring to firstname.lastname@example.org.
Patent ductus arteriosus
Repeated measures analysis of variance
Very low birth weight
Noori S, Michael M, Friedlich P, Bright B, Gottipati V, Seri I, et al. Failure of ductus arteriosus closure is associated with increased mortality in preterm infants. Pediatrics. 2009;123(1):e138–44.
Neumann R, Sm S, Buhrer C. Oral ibuprofen versus intravenous ibuprofen or intravenous indomethacin for the treatment of patent ductus arteriosus in preterm infants: a systematic review and meta-analysis. Neonatology. 2012;102(1):9–15.
Koch J, Gaynelle H, Roy L, Brown S, Ramaciotti C, Rosenfeld CR. Prevalence of spontaneous closure of the ductus arteriosus in neonates at a birth weight of 1000 grams or less. Pediatrics. 2006;117(4):1113–21.
Van Overmeire B, Smets K, Lecoutere D, Van de Broek H, Weyler J, De Groote K, et al. A comparison of ibuprofen and indomethacin for closure of patent ductus arteriosus. N Engl J Med. 2000;343(10):674–81.
Chorne N, Jegatheesan P, Lin E, Shi R, Clyman RI. Risk factors for persistent ductus arteriosus patency during indomethacin treatment. J Pediatr. 2007;151(6):629–34.
Heuchan AM, Clyman RI. Managing the patent ductus arteriosus: current treatment options. Arch Dis Child Fetal Neonatal Ed. 2014;99(5):F431–6.
El Hajjar M, Vaksmann G, Rakza T, Kongolo G, Storme L. Severity of the ductal shunt: a comparison of different markers. Arch Dis Child Fetal Neonatal Ed. 2005;90(5):F419–22.
Desandes R, Jellimann JM, Rouabah M, Haddad F, Desandes E, Boubred F, et al. Echocardiography as a guide for patent ductus arteriosus ibuprofen treatment and efficacy prediction. Pediactr Crit Care Med. 2012;13(3):324–7.
Sehgal A, McNamara PJ. Does echocardiography facilitate determination of hemodynamic significance attributable to the ductus arteriosus? Eur J Pediatr. 2009;168(8):907–14.
Walther FJ, Kim D, Ebrahimi M, Siassi B. Pulsed Doppler measurement of left ventricular output as early predictor of symptomatic patent ductus arteriosus in very preterm infants. Biol Neonate. 1989;56(3):121–8.
Hirsimäki H, Kero P, Wanne O, Erkkola R, Makoi Z. Doppler-derived cardiac output in healthy newborn infants in relation to physiological patency of the ductus arteriosus. Pediatr Cardiol. 1988;9(2):79–83.
Shimada S, Kasai T, Konishi M, Fujiwara T. Effects of patent ductus arteriosus on left ventricular output and organ blood flows in preterm infants with respiratory distress syndrome treated with surfactant. J Pediatr. 1994;125(2):270–7.
Lindner W, Seidel M, Versmold HT, Dohlemann C, Riegel KP. Stroke volume and left ventricular output in preterm infants with patent ductus arteriosus. Pedaitr Res. 1990;27(3):278–81.
El-Khuffash A, Jain A, McNamara P. Ligation of the patent ductus arteriosus in preterm infants: understanding the physiology. J Pediatr. 2013;162(6):1100–6.
Mertens L, Seri I, Marek J, Arlettaz R, Barker P, McNamara P, et al. Targeted neonatal echocardiography in the neonatal intensive care unit: practice guidelines and recommendations for training. Writing group of the American Society of Echocardiography (ASE) in collaboration with the European Association of Echocardiography (EAE) and the Association for European Pediatric Cardiologists (AEPC). J Am Soc Echocardiogr. 2011;24(10):1057–78.
de Boode WP. Cardiac output monitoring in newborns. Early Hum Dev. 2010;86(3):143–8.
Noori S, Drabu B, Soleymani S, Seri I. Continuous non-invasive cardiac output measurements in the neonate by electrical velocimetry: a comparison with echocardiography. Arch Dis Child Fetal Neonatal Ed. 2012;97(5):F340–3.
Song R, Rich W, Kim JH, Finer NN, Katheria AC. The use of electrical cardiometry for continuous cardiac output monitoring in preterm neonates: a validation study. Am J Perinatol. 2014;31(12):1105–10.
Grollmuss O, Gonzalez P. Non-invasive cardiac output measurement in low and very low birth weight infants: a method comparison. Front Pediatr. 2014;2:16.
Hsu KH, Wu TW, Wu IH, Lai MY, Hsu SY, Huang HW, et al. Electrical cardiometry to monitor cardiac output in preterm infants with patent ductus arteriosus: a comparison with echocardiography. Neonatology. 2017;112(3):231–7.
Hsu KH, Wu TW, Wang YC, Lim WH, Lee CC, Lien R. Hemodynamic reference for neonates of different age and weight: a pilot study with electrical cardiometry. J Perinatol. 2016;36(6):481–5.
Lien R, Hsu KH, Chu JJ, Chang YS. Hemodynamic alterations recorded by electrical cardiometry during ligation of ductus arteriosus in preterm infants. Eur J Pediatr. 2015;174(4):543–50.
Rodriguez Sanchez de la Blanca A, Sanchez Luna M, Gonzalez Pacheco N, Arriaga Redondo M, Navarro Patino N. Electrical velocimetry for non-invasive monitoring of the closure of the ductus arteriosus in preterm infants. Eur J Pediatr. 2018;177(2):229–35.
Padbury JF, Agata Y, Baylen BG, Ludlow JK, Polk DH, Goldblatt E, et al. Dopamine pharmacokinetics in critically ill newborn infants. J Pediatr. 1987;110(2):293–8.
Kluckow M, Evans N. Superior vena cava flow in newborn infants: a novel marker of systemic blood flow. Arch Dis Child Fetal Neonatal Ed. 2000;82(3):F182–7.
Suzmura H, Nitta A, Tanaka O. Diastolic flow velocity of left pulmonary artery of patent ductus arteriosus in preterm infants. Pediatr Int. 2001;43:146–51.
This study was supported by the Ministry of Health and Welfare of Taiwan aiming to improve quality of pediatric critical care. The funding body had no role in designing the study, collection, analysis, and interpretation of data, or in writing the manuscript.
Ethics approval and consent to participate
This study was approved by the Institutional Review Board (IRB) of Chang Gung Memorial Hospital Linkou Branch (project number: 104 - 9357A).
Consent for publication
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Hsu, KH., Wu, TW., Wu, IH. et al. Baseline cardiac output and its alterations during ibuprofen treatment for patent ductus arteriosus in preterm infants. BMC Pediatr 19, 179 (2019). https://doi.org/10.1186/s12887-019-1560-1
- Cardiac output
- Electrical cardiometry
- Non-invasive monitor
- Patent ductus arteriosus
- Preterm infant